Approximate frequency in de-novo AML | Frequency in CN AML | Strong associations | Not recorded with | Outlook | |
NPM1 | 35 percent | 50 percent | CN AML, FLT3-ITD, FLT3-TKD, DNMT3A, IDH1, IDH2 | CEBPA double mutant | Favorable in patients with CN AML and in elderly patients |
CEBPA | 7 percent | 8 to 19 percent | CN AML, FLT3-ITD | NPM1 | Favorable in patients with CN AML (if biallelic) |
FLT3-ITD | 20 to 25 percent | 30 to 35 percent | CN AML, APL, t(6;9), NPM1 | Adverse in patients with CN AML; could vary with allelic burden; no clear effect in patients with APL | |
FLT3-TKD | 5 percent | 14 percent | CN AML, NPM1 | Controversial | |
KIT | 25 percent | Core binding factor leukemias | Most other karyotypes | Adverse in adult patients with core binding factor leukemias | |
TET2 | 8 to 12 percent | 23 percent | Possibly CN AML | IDH1, IDH2 | Controversial |
DNMT3A | 14 to 22 percent | 20 to 33 percent | CN AML, NPM1, FLT3 | Core binding factor leukemias, CEBPA, MLL translocations | Possibly adverse in patients with CN AML |
IDH1, IDH2 | 8 to 16 percent | 30 percent | CN AML, NPM1, FLT3 | TET2, WT1 | Controversial |
ASXL1 | 5 to 30 percent | About 10 percent | Uncommon with NPM1 and FLT3 | Possibly CEBPA | Adverse in patients with CN AML and older patients; more common in older patients |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟